Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 511 entries
Sorted by: Best Match Show Resources per page
Corrigendum to The polymorphism XRCC1 Arg194Trp and 8-hydroxydeoxyguanosine increased susceptibility to arsenic-related renal cell carcinoma. Toxicology and Applied Pharmacology 332 (2017) 1-7.

Toxicology and applied pharmacology

Hsueh YM, Lin YC, Chen WJ, Huang CY, Shiue HS, Pu YS, Chen CH, Su CT.
PMID: 30048668
Toxicol Appl Pharmacol. 2018 Oct 01;356:139. doi: 10.1016/j.taap.2018.07.022. Epub 2018 Jul 23.

No abstract available.

Cite
Hsueh YM, Lin YC, Chen WJ, et al. Corrigendum to The polymorphism XRCC1 Arg194Trp and 8-hydroxydeoxyguanosine increased susceptibility to arsenic-related renal cell carcinoma. Toxicology and Applied Pharmacology 332 (2017) 1-7. Toxicol Appl Pharmacol. 2018;356:139doi: 10.1016/j.taap.2018.07.022.
Hsueh, Y. M., Lin, Y. C., Chen, W. J., Huang, C. Y., Shiue, H. S., Pu, Y. S., Chen, C. H., & Su, C. T. (2018). Corrigendum to The polymorphism XRCC1 Arg194Trp and 8-hydroxydeoxyguanosine increased susceptibility to arsenic-related renal cell carcinoma. Toxicology and Applied Pharmacology 332 (2017) 1-7. Toxicology and applied pharmacology, 356139. https://doi.org/10.1016/j.taap.2018.07.022
Hsueh, Yu-Mei, et al. "Corrigendum to The polymorphism XRCC1 Arg194Trp and 8-hydroxydeoxyguanosine increased susceptibility to arsenic-related renal cell carcinoma. Toxicology and Applied Pharmacology 332 (2017) 1-7." Toxicology and applied pharmacology vol. 356 (2018): 139. doi: https://doi.org/10.1016/j.taap.2018.07.022
Hsueh YM, Lin YC, Chen WJ, Huang CY, Shiue HS, Pu YS, Chen CH, Su CT. Corrigendum to The polymorphism XRCC1 Arg194Trp and 8-hydroxydeoxyguanosine increased susceptibility to arsenic-related renal cell carcinoma. Toxicology and Applied Pharmacology 332 (2017) 1-7. Toxicol Appl Pharmacol. 2018 Oct 01;356:139. doi: 10.1016/j.taap.2018.07.022. Epub 2018 Jul 23. PMID: 30048668.
Copy Download .nbib Format: NLM
Neonatal metformin short exposure inhibits male reproductive dysfunction caused by a high-fat diet in adult rats.

Toxicology and applied pharmacology

Vieira HR, Gonçalves GD, Alves VS, de Melo MAB, Borges SC, Klagenberg J, Neves CQ, Previate C, Saavedra LPJ, Siervo GEML, Malta A, Prado MAAC, Palma-Rigo K, Buttow NC, Fernandes GSA, Mathias PCF.
PMID: 34481828
Toxicol Appl Pharmacol. 2021 Oct 15;429:115712. doi: 10.1016/j.taap.2021.115712. Epub 2021 Sep 02.

Metformin (Met) is widely used to control blood glucose levels and acts on various organs, including reproductive tissues, to improve reproductive and lifespan. This study evaluated whether neonatal Met exposure prevented male reproductive dysfunction caused by being overweight during...

Cite
Vieira HR, Gonçalves GD, Alves VS, et al. Neonatal metformin short exposure inhibits male reproductive dysfunction caused by a high-fat diet in adult rats. Toxicol Appl Pharmacol. 2021;429:115712doi: 10.1016/j.taap.2021.115712.
Vieira, H. R., Gonçalves, G. D., Alves, V. S., de Melo, M. A. B., Borges, S. C., Klagenberg, J., Neves, C. Q., Previate, C., Saavedra, L. P. J., Siervo, G. E. M. L., Malta, A., Prado, M. A. A. C., Palma-Rigo, K., Buttow, N. C., Fernandes, G. S. A., & Mathias, P. C. F. (2021). Neonatal metformin short exposure inhibits male reproductive dysfunction caused by a high-fat diet in adult rats. Toxicology and applied pharmacology, 429115712. https://doi.org/10.1016/j.taap.2021.115712
Vieira, Henrique Rodrigues, et al. "Neonatal metformin short exposure inhibits male reproductive dysfunction caused by a high-fat diet in adult rats." Toxicology and applied pharmacology vol. 429 (2021): 115712. doi: https://doi.org/10.1016/j.taap.2021.115712
Vieira HR, Gonçalves GD, Alves VS, de Melo MAB, Borges SC, Klagenberg J, Neves CQ, Previate C, Saavedra LPJ, Siervo GEML, Malta A, Prado MAAC, Palma-Rigo K, Buttow NC, Fernandes GSA, Mathias PCF. Neonatal metformin short exposure inhibits male reproductive dysfunction caused by a high-fat diet in adult rats. Toxicol Appl Pharmacol. 2021 Oct 15;429:115712. doi: 10.1016/j.taap.2021.115712. Epub 2021 Sep 02. PMID: 34481828.
Copy Download .nbib Format: NLM
PARP inhibitor BMN-673 induced apoptosis by trapping PARP-1 and inhibiting base excision repair via modulation of pol-β in chromatin of breast cancer cells.

Toxicology and applied pharmacology

Sethy C, Kundu CN.
PMID: 34998856
Toxicol Appl Pharmacol. 2022 Jan 05;436:115860. doi: 10.1016/j.taap.2021.115860. Epub 2022 Jan 05.

PARP inhibitors emerged as clinically effective anti-tumor agents in combination with DNA damaging agents but the toxicity of DNA damaging agents and their off-target effects caused serious problems in cancer therapy. They confer cytotoxicity in cancer cells both by...

Cite
Sethy C, Kundu CN. PARP inhibitor BMN-673 induced apoptosis by trapping PARP-1 and inhibiting base excision repair via modulation of pol-β in chromatin of breast cancer cells. Toxicol Appl Pharmacol. 2022;436:115860doi: 10.1016/j.taap.2021.115860.
Sethy, C., & Kundu, C. N. (2022). PARP inhibitor BMN-673 induced apoptosis by trapping PARP-1 and inhibiting base excision repair via modulation of pol-β in chromatin of breast cancer cells. Toxicology and applied pharmacology, 436115860. https://doi.org/10.1016/j.taap.2021.115860
Sethy, Chinmayee, and Kundu, Chanakya Nath. "PARP inhibitor BMN-673 induced apoptosis by trapping PARP-1 and inhibiting base excision repair via modulation of pol-β in chromatin of breast cancer cells." Toxicology and applied pharmacology vol. 436 (2022): 115860. doi: https://doi.org/10.1016/j.taap.2021.115860
Sethy C, Kundu CN. PARP inhibitor BMN-673 induced apoptosis by trapping PARP-1 and inhibiting base excision repair via modulation of pol-β in chromatin of breast cancer cells. Toxicol Appl Pharmacol. 2022 Jan 05;436:115860. doi: 10.1016/j.taap.2021.115860. Epub 2022 Jan 05. PMID: 34998856.
Copy Download .nbib Format: NLM
(-)-Epicatechin ameliorates cigarette smoke-induced lung inflammation via inhibiting ROS/NLRP3 inflammasome pathway in rats with COPD.

Toxicology and applied pharmacology

Tian X, Xue Y, Xie G, Zhou Y, Xiao H, Ding F, Zhang M.
PMID: 34403689
Toxicol Appl Pharmacol. 2021 Oct 15;429:115674. doi: 10.1016/j.taap.2021.115674. Epub 2021 Aug 14.

Chronic obstructive pulmonary disease (COPD) with increased morbidity and mortality is a worldwide healthcare challenge closely associated with cigarette smoking (CS). Currently, there is no effective therapeutic strategy to control inflammation in COPD patients. The present study tested the...

Cite
Tian X, Xue Y, Xie G, et al. (-)-Epicatechin ameliorates cigarette smoke-induced lung inflammation via inhibiting ROS/NLRP3 inflammasome pathway in rats with COPD. Toxicol Appl Pharmacol. 2021;429:115674doi: 10.1016/j.taap.2021.115674.
Tian, X., Xue, Y., Xie, G., Zhou, Y., Xiao, H., Ding, F., & Zhang, M. (2021). (-)-Epicatechin ameliorates cigarette smoke-induced lung inflammation via inhibiting ROS/NLRP3 inflammasome pathway in rats with COPD. Toxicology and applied pharmacology, 429115674. https://doi.org/10.1016/j.taap.2021.115674
Tian, Xue, et al. "(-)-Epicatechin ameliorates cigarette smoke-induced lung inflammation via inhibiting ROS/NLRP3 inflammasome pathway in rats with COPD." Toxicology and applied pharmacology vol. 429 (2021): 115674. doi: https://doi.org/10.1016/j.taap.2021.115674
Tian X, Xue Y, Xie G, Zhou Y, Xiao H, Ding F, Zhang M. (-)-Epicatechin ameliorates cigarette smoke-induced lung inflammation via inhibiting ROS/NLRP3 inflammasome pathway in rats with COPD. Toxicol Appl Pharmacol. 2021 Oct 15;429:115674. doi: 10.1016/j.taap.2021.115674. Epub 2021 Aug 14. PMID: 34403689.
Copy Download .nbib Format: NLM
Evaluation of chronic toxicity of cyclocreatine in beagle dogs after oral gavage administration for up to 23 weeks.

Toxicology and applied pharmacology

Wallery JJ, Kale VP, Novak J, Gibbs S, Do MT, McKew JC, Terse PS.
PMID: 34411581
Toxicol Appl Pharmacol. 2021 Nov 01;430:115680. doi: 10.1016/j.taap.2021.115680. Epub 2021 Aug 17.

Cyclocreatine (LUM-001) was evaluated for chronic toxicity (23 weeks) in beagle dogs to support clinical development in patients with creatine transporter deficiency (CTD) disorder. Deionized water (vehicle control) or cyclocreatine was administered by oral gavage twice daily (12 ±...

Cite
Wallery JJ, Kale VP, Novak J, et al. Evaluation of chronic toxicity of cyclocreatine in beagle dogs after oral gavage administration for up to 23 weeks. Toxicol Appl Pharmacol. 2021;430:115680doi: 10.1016/j.taap.2021.115680.
Wallery, J. J., Kale, V. P., Novak, J., Gibbs, S., Do, M. T., McKew, J. C., & Terse, P. S. (2021). Evaluation of chronic toxicity of cyclocreatine in beagle dogs after oral gavage administration for up to 23 weeks. Toxicology and applied pharmacology, 430115680. https://doi.org/10.1016/j.taap.2021.115680
Wallery, Jeffrey J, et al. "Evaluation of chronic toxicity of cyclocreatine in beagle dogs after oral gavage administration for up to 23 weeks." Toxicology and applied pharmacology vol. 430 (2021): 115680. doi: https://doi.org/10.1016/j.taap.2021.115680
Wallery JJ, Kale VP, Novak J, Gibbs S, Do MT, McKew JC, Terse PS. Evaluation of chronic toxicity of cyclocreatine in beagle dogs after oral gavage administration for up to 23 weeks. Toxicol Appl Pharmacol. 2021 Nov 01;430:115680. doi: 10.1016/j.taap.2021.115680. Epub 2021 Aug 17. PMID: 34411581; PMCID: PMC8549071.
Copy Download .nbib Format: NLM
Improved nonclinical safety profile of a novel, highly selective inhibitor of the immunoproteasome subunit LMP7 (M3258).

Toxicology and applied pharmacology

Sloot W, Glaser N, Hansen A, Hellmann J, Jaeckel S, Johannes S, Knippel A, Lai V, Onidi M.
PMID: 34419493
Toxicol Appl Pharmacol. 2021 Oct 15;429:115695. doi: 10.1016/j.taap.2021.115695. Epub 2021 Aug 20.

M3258 is the first selective inhibitor of the immunoproteasome subunit LMP7 (Large multifunctional protease 7) in early clinical development with the potential to improve therapeutic utility in patients of multiple myeloma (MM) or other hematological malignancies. Safety pharmacology studies...

Cite
Sloot W, Glaser N, Hansen A, et al. Improved nonclinical safety profile of a novel, highly selective inhibitor of the immunoproteasome subunit LMP7 (M3258). Toxicol Appl Pharmacol. 2021;429:115695doi: 10.1016/j.taap.2021.115695.
Sloot, W., Glaser, N., Hansen, A., Hellmann, J., Jaeckel, S., Johannes, S., Knippel, A., Lai, V., & Onidi, M. (2021). Improved nonclinical safety profile of a novel, highly selective inhibitor of the immunoproteasome subunit LMP7 (M3258). Toxicology and applied pharmacology, 429115695. https://doi.org/10.1016/j.taap.2021.115695
Sloot, Willem, et al. "Improved nonclinical safety profile of a novel, highly selective inhibitor of the immunoproteasome subunit LMP7 (M3258)." Toxicology and applied pharmacology vol. 429 (2021): 115695. doi: https://doi.org/10.1016/j.taap.2021.115695
Sloot W, Glaser N, Hansen A, Hellmann J, Jaeckel S, Johannes S, Knippel A, Lai V, Onidi M. Improved nonclinical safety profile of a novel, highly selective inhibitor of the immunoproteasome subunit LMP7 (M3258). Toxicol Appl Pharmacol. 2021 Oct 15;429:115695. doi: 10.1016/j.taap.2021.115695. Epub 2021 Aug 20. PMID: 34419493.
Copy Download .nbib Format: NLM
Circadian disruption and cisplatin chronotherapy for mammary carcinoma.

Toxicology and applied pharmacology

Koritala BSC, Porter KI, Sarkar S, Gaddameedhi S.
PMID: 34998857
Toxicol Appl Pharmacol. 2022 Jan 05;436:115863. doi: 10.1016/j.taap.2022.115863. Epub 2022 Jan 05.

Solid tumors are commonly treated with cisplatin, which can cause off-target side effects in cancer patients. Chronotherapy is a potential strategy to reduce drug toxicity. To determine the effectiveness of timed-cisplatin treatment in mammals, we compared two conditions: clock...

Cite
Koritala BSC, Porter KI, Sarkar S, et al. Circadian disruption and cisplatin chronotherapy for mammary carcinoma. Toxicol Appl Pharmacol. 2022;436:115863doi: 10.1016/j.taap.2022.115863.
Koritala, B. S. C., Porter, K. I., Sarkar, S., & Gaddameedhi, S. (2022). Circadian disruption and cisplatin chronotherapy for mammary carcinoma. Toxicology and applied pharmacology, 436115863. https://doi.org/10.1016/j.taap.2022.115863
Koritala, Bala S C, et al. "Circadian disruption and cisplatin chronotherapy for mammary carcinoma." Toxicology and applied pharmacology vol. 436 (2022): 115863. doi: https://doi.org/10.1016/j.taap.2022.115863
Koritala BSC, Porter KI, Sarkar S, Gaddameedhi S. Circadian disruption and cisplatin chronotherapy for mammary carcinoma. Toxicol Appl Pharmacol. 2022 Jan 05;436:115863. doi: 10.1016/j.taap.2022.115863. Epub 2022 Jan 05. PMID: 34998857.
Copy Download .nbib Format: NLM
Scopoletin and umbelliferone protect hepatocytes against palmitate- and bile acid-induced cell death by reducing endoplasmic reticulum stress and oxidative stress.

Toxicology and applied pharmacology

Wu Z, Geng Y, Buist-Homan M, Moshage H.
PMID: 34979142
Toxicol Appl Pharmacol. 2021 Dec 31;436:115858. doi: 10.1016/j.taap.2021.115858. Epub 2021 Dec 31.

BACKGROUND: The number of patients with non-alcoholic fatty liver disease (NAFLD) is rapidly increasing due to the growing epidemic of obesity. Non-alcoholic steatohepatitis (NASH), the inflammatory stage of NAFLD, is characterized by lipid accumulation in hepatocytes, chronic inflammation and...

Cite
Wu Z, Geng Y, Buist-Homan M, et al. Scopoletin and umbelliferone protect hepatocytes against palmitate- and bile acid-induced cell death by reducing endoplasmic reticulum stress and oxidative stress. Toxicol Appl Pharmacol. 2021;436:115858doi: 10.1016/j.taap.2021.115858.
Wu, Z., Geng, Y., Buist-Homan, M., & Moshage, H. (2021). Scopoletin and umbelliferone protect hepatocytes against palmitate- and bile acid-induced cell death by reducing endoplasmic reticulum stress and oxidative stress. Toxicology and applied pharmacology, 436115858. https://doi.org/10.1016/j.taap.2021.115858
Wu, Zongmei, et al. "Scopoletin and umbelliferone protect hepatocytes against palmitate- and bile acid-induced cell death by reducing endoplasmic reticulum stress and oxidative stress." Toxicology and applied pharmacology vol. 436 (2021): 115858. doi: https://doi.org/10.1016/j.taap.2021.115858
Wu Z, Geng Y, Buist-Homan M, Moshage H. Scopoletin and umbelliferone protect hepatocytes against palmitate- and bile acid-induced cell death by reducing endoplasmic reticulum stress and oxidative stress. Toxicol Appl Pharmacol. 2021 Dec 31;436:115858. doi: 10.1016/j.taap.2021.115858. Epub 2021 Dec 31. PMID: 34979142.
Copy Download .nbib Format: NLM
Ribavirin inhibits the growth and ascites formation of hepatocellular carcinoma through downregulation of type I CARM1 and type II PRMT5.

Toxicology and applied pharmacology

Tian Y, Yang W, Yang R, Zhang Q, Hao L, Bian E, Yang Y, Huang X, Wu Y, Zhang B.
PMID: 34919946
Toxicol Appl Pharmacol. 2021 Dec 14;435:115829. doi: 10.1016/j.taap.2021.115829. Epub 2021 Dec 14.

Type I co-activator-associated arginine methyltransferase 1 (CARM1) and type II protein arginine methyltransferase 5 (PRMT5) are highly expressed in multiple cancers including liver cancer and their overexpression contributes to poor prognosis, thus making them promising therapeutic targets. Here, we...

Cite
Tian Y, Yang W, Yang R, et al. Ribavirin inhibits the growth and ascites formation of hepatocellular carcinoma through downregulation of type I CARM1 and type II PRMT5. Toxicol Appl Pharmacol. 2021;435:115829doi: 10.1016/j.taap.2021.115829.
Tian, Y., Yang, W., Yang, R., Zhang, Q., Hao, L., Bian, E., Yang, Y., Huang, X., Wu, Y., & Zhang, B. (2021). Ribavirin inhibits the growth and ascites formation of hepatocellular carcinoma through downregulation of type I CARM1 and type II PRMT5. Toxicology and applied pharmacology, 435115829. https://doi.org/10.1016/j.taap.2021.115829
Tian, Yizhen, et al. "Ribavirin inhibits the growth and ascites formation of hepatocellular carcinoma through downregulation of type I CARM1 and type II PRMT5." Toxicology and applied pharmacology vol. 435 (2021): 115829. doi: https://doi.org/10.1016/j.taap.2021.115829
Tian Y, Yang W, Yang R, Zhang Q, Hao L, Bian E, Yang Y, Huang X, Wu Y, Zhang B. Ribavirin inhibits the growth and ascites formation of hepatocellular carcinoma through downregulation of type I CARM1 and type II PRMT5. Toxicol Appl Pharmacol. 2021 Dec 14;435:115829. doi: 10.1016/j.taap.2021.115829. Epub 2021 Dec 14. PMID: 34919946.
Copy Download .nbib Format: NLM
The therapeutic effect of hesperetin on doxorubicin-induced testicular toxicity: Potential roles of the mechanistic target of rapamycin kinase (mTOR) and dynamin-related protein 1 (DRP1).

Toxicology and applied pharmacology

Tektemur A, Tektemur NK, Güzel EE.
PMID: 34933056
Toxicol Appl Pharmacol. 2021 Dec 18;435:115833. doi: 10.1016/j.taap.2021.115833. Epub 2021 Dec 18.

Clinical utilization of doxorubicin (DOX), which is a commonly used chemotherapeutic, is restricted due to toxic effects on various tissues. Using hesperetin (HST), an antioxidant used in Chinese traditional medicine protects testis against DOX-induced toxicity although the molecular mechanisms...

Cite
Tektemur A, Tektemur NK, Güzel EE. The therapeutic effect of hesperetin on doxorubicin-induced testicular toxicity: Potential roles of the mechanistic target of rapamycin kinase (mTOR) and dynamin-related protein 1 (DRP1). Toxicol Appl Pharmacol. 2021;435:115833doi: 10.1016/j.taap.2021.115833.
Tektemur, A., Tektemur, N. K., & Güzel, E. E. (2021). The therapeutic effect of hesperetin on doxorubicin-induced testicular toxicity: Potential roles of the mechanistic target of rapamycin kinase (mTOR) and dynamin-related protein 1 (DRP1). Toxicology and applied pharmacology, 435115833. https://doi.org/10.1016/j.taap.2021.115833
Tektemur, Ahmet, et al. "The therapeutic effect of hesperetin on doxorubicin-induced testicular toxicity: Potential roles of the mechanistic target of rapamycin kinase (mTOR) and dynamin-related protein 1 (DRP1)." Toxicology and applied pharmacology vol. 435 (2021): 115833. doi: https://doi.org/10.1016/j.taap.2021.115833
Tektemur A, Tektemur NK, Güzel EE. The therapeutic effect of hesperetin on doxorubicin-induced testicular toxicity: Potential roles of the mechanistic target of rapamycin kinase (mTOR) and dynamin-related protein 1 (DRP1). Toxicol Appl Pharmacol. 2021 Dec 18;435:115833. doi: 10.1016/j.taap.2021.115833. Epub 2021 Dec 18. PMID: 34933056.
Copy Download .nbib Format: NLM
Ribavirin inhibits the growth and ascites formation of hepatocellular carcinoma through downregulation of type I CARM1 and type II PRMT5.

Toxicology and applied pharmacology

Tian Y, Yang W, Yang R, Zhang Q, Hao L, Bian E, Yang Y, Huang X, Wu Y, Zhang B.
PMID: 34919946
Toxicol Appl Pharmacol. 2021 Dec 14;435:115829. doi: 10.1016/j.taap.2021.115829. Epub 2021 Dec 14.

Type I co-activator-associated arginine methyltransferase 1 (CARM1) and type II protein arginine methyltransferase 5 (PRMT5) are highly expressed in multiple cancers including liver cancer and their overexpression contributes to poor prognosis, thus making them promising therapeutic targets. Here, we...

Cite
Tian Y, Yang W, Yang R, et al. Ribavirin inhibits the growth and ascites formation of hepatocellular carcinoma through downregulation of type I CARM1 and type II PRMT5. Toxicol Appl Pharmacol. 2021;435:115829doi: 10.1016/j.taap.2021.115829.
Tian, Y., Yang, W., Yang, R., Zhang, Q., Hao, L., Bian, E., Yang, Y., Huang, X., Wu, Y., & Zhang, B. (2021). Ribavirin inhibits the growth and ascites formation of hepatocellular carcinoma through downregulation of type I CARM1 and type II PRMT5. Toxicology and applied pharmacology, 435115829. https://doi.org/10.1016/j.taap.2021.115829
Tian, Yizhen, et al. "Ribavirin inhibits the growth and ascites formation of hepatocellular carcinoma through downregulation of type I CARM1 and type II PRMT5." Toxicology and applied pharmacology vol. 435 (2021): 115829. doi: https://doi.org/10.1016/j.taap.2021.115829
Tian Y, Yang W, Yang R, Zhang Q, Hao L, Bian E, Yang Y, Huang X, Wu Y, Zhang B. Ribavirin inhibits the growth and ascites formation of hepatocellular carcinoma through downregulation of type I CARM1 and type II PRMT5. Toxicol Appl Pharmacol. 2021 Dec 14;435:115829. doi: 10.1016/j.taap.2021.115829. Epub 2021 Dec 14. PMID: 34919946.
Copy Download .nbib Format: NLM
The therapeutic effect of hesperetin on doxorubicin-induced testicular toxicity: Potential roles of the mechanistic target of rapamycin kinase (mTOR) and dynamin-related protein 1 (DRP1).

Toxicology and applied pharmacology

Tektemur A, Tektemur NK, Güzel EE.
PMID: 34933056
Toxicol Appl Pharmacol. 2021 Dec 18;435:115833. doi: 10.1016/j.taap.2021.115833. Epub 2021 Dec 18.

Clinical utilization of doxorubicin (DOX), which is a commonly used chemotherapeutic, is restricted due to toxic effects on various tissues. Using hesperetin (HST), an antioxidant used in Chinese traditional medicine protects testis against DOX-induced toxicity although the molecular mechanisms...

Cite
Tektemur A, Tektemur NK, Güzel EE. The therapeutic effect of hesperetin on doxorubicin-induced testicular toxicity: Potential roles of the mechanistic target of rapamycin kinase (mTOR) and dynamin-related protein 1 (DRP1). Toxicol Appl Pharmacol. 2021;435:115833doi: 10.1016/j.taap.2021.115833.
Tektemur, A., Tektemur, N. K., & Güzel, E. E. (2021). The therapeutic effect of hesperetin on doxorubicin-induced testicular toxicity: Potential roles of the mechanistic target of rapamycin kinase (mTOR) and dynamin-related protein 1 (DRP1). Toxicology and applied pharmacology, 435115833. https://doi.org/10.1016/j.taap.2021.115833
Tektemur, Ahmet, et al. "The therapeutic effect of hesperetin on doxorubicin-induced testicular toxicity: Potential roles of the mechanistic target of rapamycin kinase (mTOR) and dynamin-related protein 1 (DRP1)." Toxicology and applied pharmacology vol. 435 (2021): 115833. doi: https://doi.org/10.1016/j.taap.2021.115833
Tektemur A, Tektemur NK, Güzel EE. The therapeutic effect of hesperetin on doxorubicin-induced testicular toxicity: Potential roles of the mechanistic target of rapamycin kinase (mTOR) and dynamin-related protein 1 (DRP1). Toxicol Appl Pharmacol. 2021 Dec 18;435:115833. doi: 10.1016/j.taap.2021.115833. Epub 2021 Dec 18. PMID: 34933056.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 511 entries